Enhancing non-viral gene editing, processing, & expansion of T & NK cells
Cell & Gene Therapy 2023; 9(2), 137
DOI: 10.18609/cgti.2023.017
A key focus in cell therapy manufacturing is the development of closed, automated manufacturing processes to help reduce costs and increase the speed of getting treatments to patients. The Gibco™ CTS™ Rotea™ Counterflow Centrifugation system and the Gibco CTS Xenon™ Electroporation System are powerful modular tools in the quest towards creating a closed cell therapy manufacturing process by providing exceptional performance and helping to reduce contamination in a cell therapy manufacturing workflow. This poster provides a summary of how Thermo Fisher Scientific technologies have been proven for effective use in chimeric antigen receptor (CAR)-T cell workflow optimization and natural killer (NK) cell engineering.
You can view or download the poster here.
If you are interested in learning more, you can watch the webinar here or read the full article here.
Authorship & conflict of interest
Contributions: All named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Acknowledgements: None
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest.
Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article.
Article & copyright information
Copyright: Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
Attribution: Copyright © 2023 Thermo Fisher Scientific. Published by Cell and Gene Therapy Insights under Creative Commons License Deed CC BY NC ND 4.0.
Article source: From a webinar recorded on: Dec 8 2022; Publication date: Mar 2 2023.